tetano
Editor, Senior Moderator
JMIR Public Health Surveill
. 2023 May 8;9:e39700.
doi: 10.2196/39700. Comparing the Use of a Mobile App and a Web-Based Notification Platform for Surveillance of Adverse Events Following Influenza Immunization: Randomized Controlled Trial
A Brianne Bota[SUP] 1 [/SUP], Julie A Bettinger[SUP] 2 [/SUP], Shirley Sarfo-Mensah[SUP] 1 [/SUP], Jimmy Lopez[SUP] 2 [/SUP], David P Smith[SUP] 1 [/SUP], Katherine M Atkinson[SUP] 3 [/SUP], Cameron Bell[SUP] 4 [/SUP], Kim Marty[SUP] 2 [/SUP], Mohamed Serhan[SUP] 1 [/SUP], David T Zhu[SUP] 1 5 [/SUP], Anne E McCarthy[SUP] 6 [/SUP], Kumanan Wilson[SUP] 1 4 6 7 [/SUP]
Affiliations
Background: Vaccine safety surveillance is a core component of vaccine pharmacovigilance. In Canada, active, participant-centered vaccine surveillance is available for influenza vaccines and has been used for COVID-19 vaccines.
Objective: The objective of this study is to evaluate the effectiveness and feasibility of using a mobile app for reporting participant-centered seasonal influenza adverse events following immunization (AEFIs) compared to a web-based notification system.
Methods: Participants were randomized to influenza vaccine safety reporting via a mobile app or a web-based notification platform. All participants were invited to complete a user experience survey.
Results: Among the 2408 randomized participants, 1319 (54%) completed their safety survey 1 week after vaccination, with a higher completion rate among the web-based notification platform users (767/1196, 64%) than among mobile app users (552/1212, 45%; P<.001). Ease-of-use ratings were high for the web-based notification platform users (99% strongly agree or agree) and 88.8% of them strongly agreed or agreed that the system made reporting AEFIs easier. Web-based notification platform users supported the statement that a web-based notification-only approach would make it easier for public health professionals to detect vaccine safety signals (91.4%, agreed or strongly agreed).
Conclusions: Participants in this study were significantly more likely to respond to a web-based safety survey rather than within a mobile app. These results suggest that mobile apps present an additional barrier for use compared to the web-based notification-only approach.
Trial registration: ClinicalTrials.gov NCT05794113; https://clinicaltrials.gov/show/NCT05794113.
Keywords: active participant–centered reporting; adverse event reporting; apps; campaign; health technology; immunization; influenza; mobile; mobile apps; pharmacovigilance; safety; surveillance; vaccine.
. 2023 May 8;9:e39700.
doi: 10.2196/39700. Comparing the Use of a Mobile App and a Web-Based Notification Platform for Surveillance of Adverse Events Following Influenza Immunization: Randomized Controlled Trial
A Brianne Bota[SUP] 1 [/SUP], Julie A Bettinger[SUP] 2 [/SUP], Shirley Sarfo-Mensah[SUP] 1 [/SUP], Jimmy Lopez[SUP] 2 [/SUP], David P Smith[SUP] 1 [/SUP], Katherine M Atkinson[SUP] 3 [/SUP], Cameron Bell[SUP] 4 [/SUP], Kim Marty[SUP] 2 [/SUP], Mohamed Serhan[SUP] 1 [/SUP], David T Zhu[SUP] 1 5 [/SUP], Anne E McCarthy[SUP] 6 [/SUP], Kumanan Wilson[SUP] 1 4 6 7 [/SUP]
Affiliations
- PMID: 37155240
- DOI: 10.2196/39700
Background: Vaccine safety surveillance is a core component of vaccine pharmacovigilance. In Canada, active, participant-centered vaccine surveillance is available for influenza vaccines and has been used for COVID-19 vaccines.
Objective: The objective of this study is to evaluate the effectiveness and feasibility of using a mobile app for reporting participant-centered seasonal influenza adverse events following immunization (AEFIs) compared to a web-based notification system.
Methods: Participants were randomized to influenza vaccine safety reporting via a mobile app or a web-based notification platform. All participants were invited to complete a user experience survey.
Results: Among the 2408 randomized participants, 1319 (54%) completed their safety survey 1 week after vaccination, with a higher completion rate among the web-based notification platform users (767/1196, 64%) than among mobile app users (552/1212, 45%; P<.001). Ease-of-use ratings were high for the web-based notification platform users (99% strongly agree or agree) and 88.8% of them strongly agreed or agreed that the system made reporting AEFIs easier. Web-based notification platform users supported the statement that a web-based notification-only approach would make it easier for public health professionals to detect vaccine safety signals (91.4%, agreed or strongly agreed).
Conclusions: Participants in this study were significantly more likely to respond to a web-based safety survey rather than within a mobile app. These results suggest that mobile apps present an additional barrier for use compared to the web-based notification-only approach.
Trial registration: ClinicalTrials.gov NCT05794113; https://clinicaltrials.gov/show/NCT05794113.
Keywords: active participant–centered reporting; adverse event reporting; apps; campaign; health technology; immunization; influenza; mobile; mobile apps; pharmacovigilance; safety; surveillance; vaccine.